Back
Ventas, Inc. 10K Form
Buy
75
VTR
Ventas, Inc.
Last Price:
$80.44
Seasonality Move:
7.35%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2024-05-02 | 10Q | VTR/Ventas, Inc. Quarterly |
| 2024-02-15 | 10K | VTR/Ventas, Inc. Annual |
| 2023-11-03 | 10Q | VTR/Ventas, Inc. Quarterly |
| 2023-08-04 | 10Q | VTR/Ventas, Inc. Quarterly |
| 2023-05-09 | 10Q | VTR/Ventas, Inc. Quarterly |
| 2023-02-10 | 10K | VTR/Ventas, Inc. Annual |
Receive VTR News And Ratings
See the #1 stock for the next 7 days that we like better than VTR
VTR Financial Statistics
Sales & Book Value
| Annual Sales: | $4.9B |
|---|---|
| Cash Flow: | $286.4M |
| Price / Cash Flow: | 28.96 |
| Annual Sales: | $26.33 |
| Price / Book: | 3.04 |
Profitability
| EPS (TTM): | 0.52910 |
|---|---|
| Net Income (TTM): | $247.3M |
| Gross Margin: | $918.7M |
| Return on Equity: | 2.14% |
| Return on Assets: | 0.94% |
Ventas, Inc. Earnings Forecast
Key Ventas, Inc. Financial Ratios
-
The Gross Profit Margin over the past 38 years for VTR is 18.57%.
-
The Selling, General & Administrative Expenses for VTR have been equal to 0.00% of Gross Profit Margin.
-
The Research & Development expenses have been 0.00% of Revenue.
-
The Interest Expense is 669.42% of Operating Income.
-
The Net Earning history of VTR is 1.79% of Total Revenues.
-
Per Share Earnings over the last 38 years have been positive in 22 years.
Ventas, Inc. Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | S&P500 |
|---|---|
| Industry: | Health Care REITs |
| Sector: | Real Estate |
| Current Symbol: | VTR |
| CUSIP: | 92276F |
| Website: | ventasreit.com |
Debt
| Debt-to-Equity Ratio: | 1.04 |
|---|---|
| Current Ratio: | 2.89 |
| Quick Ratio: | 1.08 |
Price-to-Earnings
| Trailing P/E Ratio: | 410.47 |
|---|---|
| Forward P/E Ratio: | 141.59 |
VTR Technical Analysis vs Fundamental Analysis
Buy
75
Ventas, Inc. (VTR)
is a Buy
Is Ventas, Inc. a Buy or a Sell?
-
Ventas, Inc. stock is rated a BuyThe current Ventas, Inc. [VTR] share price is $80.00. The Score for VTR is 75, which is 50% above its historic median score of 50, and infers lower risk than normal.